CanAssist Breast, an innovative and highly advanced prognostic test for breast cancer patients in the early stages that aids clinicians in determining whether the patient needs chemotherapy, will be exclusively marketed by global healthcare company Zydus Lifesciences Ltd.
Nearly 50% of the 2.1 million cases of breast cancer in India are hormone positive. Many patients receive chemotherapy, which may not be beneficial to them, in the absence of such prognostic tests. However, with the help of CanAssist Breast and its precise findings, clinicians can rationally advise against chemotherapy for their patients. This test was developed by OncoStem after five years of study and the collection of extensive data on breast cancer patients in India and around the world.